DEVELOPMENT AND VALIDATION FOR THE ANALYSIS OF ANTI-DIABETIC AGENT VILDAGLIPTIN IN BULK FORM AND MARKETED PHARMACEUTICAL DOSAGE FORM BY USING RP-HPLC METHOD

M. Sai Shivani[1], G.Kalyani[2]*

[1]Department of Pharmaceutical Analysis, Teegala Krishna Reddy College of Pharmacy, Medbowli, Meerpet (V), Balapur (M), Ranga Reddy (Dist), Hyderabad – 500097, Telangana*

[2]Department of Pharmaceutical Chemistry, Associate Professor, Teegala Krishna Reddy College of Pharmacy, Medbowli, Meerpet (V), Balapur (M), Ranga Reddy (Dist), Hyderabad – 500097, Telangana

ABSTRACT: ***An efficient and simple HPLC method has been developed and validated for the determination of Vildagliptin in bulk and was applied on marketed Vildagliptinproducts. The mobile phase used for the chromatographic runs consisted of Acetonitrile and Phosphate buffer (0.01M, pH-3.2)in the ratio of 30:70 v/v. The separation was achieved on a Symmetry C18 ODS (4.6mm×250mm) 5µm particle size column using isocratic mode. Drug peak were well separated and were detected by a UV detector at 246 nm. The method was linear at the concentration range 6–14 µg/ml for Vildagliptin. The method has been validated according to ICH guidelines with respect to system suitability, specificity, precision, accuracy and robustness. Vildagliptin limit of detection (LOD) and limit of quantification (LOQ) were 0.487µg/ml and 1.477µg/ml respectively.***

Key Words: Vildagliptin, RP-HPLC, Accuracy, Precision, Robustness, ICH Guidelines.

I. INTRODUCTION

Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, Vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are incretin hormones that promote insulin secretion and regulate blood glucose levels[1]. Elevated levels of GLP-1 and GIP consequently results in improved glycemic control. In clinical trials, Vildagliptin has a relatively low risk of hypoglycemia. Oral Vildagliptin was approved by the European Medicines Agency in 2008 for the treatment of type II diabetes mellitus in adults as monotherapy or in combination with [metformin], a sulfonylurea, or a thiazolidinedione in patients with inadequate glycemic control following monotherapy. It is marketed as Galvus[2]. Vildagliptin is also available as Eucreas, a fixed-dose formulation with metformin for adults in who do not adequately glycemic control from monotherapy. Vildagliptin is currently under investigation in the US.Vildagliptin is indicated in the treatment of type II diabetes mellitus in adults. As monotherapy, Vildagliptin is indicated in adults inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance[3]. It is also indicated as dual therapy in combination with metformin, a sulphonylurea, or a thiazolidinedione in adults patients with insufficient glycemic control despite maximal tolerated dose of monotherapy. The IUPAC name of Vildagliptin is (2S)-1-[2-[(3-hydroxy-1-adamantyl) amino] acetyl] pyrrolidine-2-carbonitrile.The Chemical Structure of Vildagliptinwas shown in following fig-1.



Fig.1. Chemical Structure of Vildagliptin

II. MATERIALS AND METHODS

Materials and Instruments:

The following are the list of instruments/Equipments, chemicals/reagents and standards to perform the HPLC Analysis[4] of the drug Vildagliptin.

Equipments:

Table-1: List of Equipments

S.No.	Instruments/Equipments/Apparatus
1.	HPLC WATERS with Empower2 Software with Isocratic with UV-Visible Detector.
2.	T60-LABINDIA UV – Vis spectrophotometer
3.	High Precision Electronic Balance
4.	Ultra Sonicator (Wensar wuc-2L)
5.	Thermal Oven
6.	Symmetry C_{18} Column, 250 mm x 4.6 mm and 5µm particle size
7.	P^H Analyser (ELICO)
8.	Vaccum Filtration Kit (Labindia)

Chemicals and Reagents:

Table-2: List of Chemicals used

S.No.	Name	Grade	Manufacturer/Supplier
1.	HPLC grade water	HPLC	Sd fine-Chem ltd; Mumbai
2.	Methanol	HPLC	Loba Chem; Mumbai.
3.	Ethanol	A.R.	Sd fine-Chem ltd; Mumbai
4.	Acetonitrile	HPLC	Loba Chem; Mumbai.

5.	DMSO	A.R.	Sd fine-Chem ltd; Mumbai
6.	DMF	A.R.	Sd fine-Chem ltd; Mumbai

Working Standard: Working Standard of Vildagliptin: 10ppm

Method Development:

HPLC Instrumentation & Conditions: The HPLC system[5] employed was **HPLC WATERS**with Empower2 Software with Isocratic with UV-Visible Detector.

Standard Preparation for UV-Spectrophotometer Analysis:

The Standard Stock Solutions – 10 mg of Vildagliptin standard was transferred into 10 ml volumetric flask, dissolved & make up to volume with Methanol. Further dilutions were done by transferring 1 ml of the above solution into a 10ml volumetricflask and make up to volume with methanol to get 10ppm concentration.

Itscanned in the UV spectrum[6] in the range of 200 to 400nm. This has been performed to know the maxima of Vildagliptin, so that the same wave number can be utilized in HPLC UV detector for estimating the Vildagliptin.

Fig.2. Double Beam UV Spectrophotometer

WavelengthDetection:

Thedetectionwavelengthwasselectedby dissolvingthedruginmobilephase togeta concentrationof10µg/mlforindividualandmixedstandards.Theresulting solution wasscannedin U.V range from200-400nm. The UV spectrumofVildagliptin wasobtainedandtheVildagliptin showedabsorbance'smaximaat246nm.TheUVspectraofdrugarefollows:



Fig.3. UV Spectrum of Vildagliptin (246nm)

Observation: While scanning the Vildagliptin solution we observed the maxima at 246nm. The UV spectrum has been recorded on T60-LAB INDIA make UV – Vis spectrophotometer model UV-2450.

Selection of Chromatographic Methods:

The proper selection depends upon the nature of the sample, (ionic or ion stable or neutral molecule) its molecular weight and stability. The drugs selected are polar, ionic and hence reversed phase chromatography[7] was selected.

Optimization of Column:

The method was performed with various columns like Hypersil C_{18} column, X- bridge column and X-terra (4.6 ×150mm, 5µm particle size), Symmetry C18 ODS (4.6mm×250mm) 5µm particle size Column was found to be ideal as it gave good peak shape and resolution[8] at 1ml/min flow.

Mobile Phase Optimization:
Initially the mobile phase tried was Water: Methanol and Water: Acetonitrile and Methanol with TEA Buffer with varying proportions. Finally, the mobile phase was optimized to Acetonitrile: Phosphate buffer (0.01M, pH-3.2) in the ratio of 30:70% v/vrespectively.

Estimation ofVildagliptinin bulk and pharmaceutical dosage form:

Procedure

Preparation of Mobile Phase:

Accurately measured 300 ml (300%) of HPLC Grade Acetonitrile and 700 ml of Phosphate buffer (70%) were mixed and degassed in a digital ultra sonicater for 15 minutes and then filtered through 0.45 µ filter under vacuum filter.

Preparation of 0.01M Potassium dihydrogen orthophosphate Buffer Solution:

About 1.36086grams of Potassium dihydrogen orthophosphate was weighed and transferred into a 1000ml beaker, dissolved and diluted to 1000ml with HPLC Grade water. The pH was adjusted to 3.20 with diluted orthophosphoric acid.

Diluent Preparation:

Accurately measured 300 ml (300%) of HPLC Grade Acetonitrile and 700 ml of Phosphate buffer (70%) were mixed and degassed in a digital ultra sonicater for 15 minutes and then filtered through 0.45 µ filter under vacuum filter.

Assay

Preparation of the Vildagliptinstandard solution:

Preparation of standard solution: (Vildagliptin)

Accurately weigh and transfer 10 mg of Vildagliptin, working standard into a 10ml of clean dry volumetric flasks add about 7ml of diluent and sonicate to dissolve and removal of air completely and make volume up to the mark with the diluent.

Further pipette 0.1ml of Vildagliptin from stock solution in to a 10ml volumetric flask and dilute up to the mark with diluent.

Procedure:

Inject the samples by changing the chromatographic conditions and record the chromatograms, note the conditions of proper peak elution for performing validation parameters as per ICH guidelines[13,14].

Preparation of Sample Solution:

Take average weight of Tablet and crush in a mortar by using pestle and taken weight 10 mg equivalent weight ofVildagliptinsample into a 10ml clean dry volumetric flask and add about 7ml of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent.

Procedure:

Further pipette 0.1ml of Vildagliptin from above stock solution into a 10ml volumetric flask and dilute up to the mark with diluent.

Inject the three replicate injections of standard and sample solutions and calculate the assay[9] by using formula:

$$\%ASSAY = \frac{\text{Sample area}}{\text{Standard area}} \times \frac{\text{Weight of standard}}{\text{Dilution of standard}} \times \frac{\text{Dilution of sample}}{\text{Weight of sample}} \times \frac{\text{Purity}}{100} \times \frac{\text{Weight of tablet}}{\text{Label claim}} \times 100$$

Analytical Method Validation

System Suitability

System suitability[10] is the evaluation of the components of an analytical system to show that the performance of a system meets the standards required by a method. A system suitability evaluation usually contains its own set of parameters. For chromatographic assays, these may include tailing factor, resolution, precision, capacity factor time and theoretical plates.

Accuracy:

For preparation of 50% Standard stock solution:

Further pipette 0.05ml of Vildagliptin from stock solutions in to a 10ml volumetric flask and dilute up to the mark with diluent.

For preparation of 100% Standard stock solution:

Further pipette 0.1ml of Vildagliptin from stock solutions in to a 10ml volumetric flask and dilute up to the mark with diluent.

For preparation of 150% Standard stock solution:

Further pipette 0.15 ml of Vildagliptin from stock solutions in to a 10ml volumetric flask and dilute up to the mark with diluent.

Procedure:

Inject the Three replicate injections of individual concentrations (50%, 100%, 150%) were made under the optimized conditions. Recorded the chromatograms and measured the peak responses. Calculate the Amount found and Amount added for Vildagliptin and calculate the individual recovery and mean recovery values[11].

Acceptance criteria:

The %RSD for each level should not be more than 2 .

Precision:

Repeatability

Preparation of Vildagliptin for Precision:

Further pipette 0.1 ml of Vildagliptin from stock solutions in to a 10ml volumetric flask and dilute up to the mark with diluent

The standard solution was injected for five times and measured the area for all five injections in HPLC. The %RSD for the area of five replicate injections was found to be within the specified limits.

Ruggedness

To evaluate the intermediate precision of the method, Precision was performed on different days by maintaining same conditions.

Procedure:

Day 1:

The standard solution was injected for six times and measured the area for all six injections in HPLC. The %RSD for the area of six replicate injections was found to be within the specified limits.

Day 2:

The standard solution was injected for six times and measured the area for all six injections in HPLC. The %RSD for the area of six replicate injections was found to be within the specified limits.

The % RSD for the area of five standard injections results should be not more than 2%.

Linearity:

Preparation of Level – I (6µg/ml of Vildagliptin):

Further pipette 0.06 ml of Vildagliptin from stock solutions in to a 10ml volumetric flask and dilute up to the mark with diluent.

Preparation of Level – II (8µg/ml of Vildagliptin):

Further pipette 0.08 ml of Vildagliptin from stock solutions in to a 10ml volumetric flask and dilute up to the mark with diluent.

Preparation of Level – III (10µg/ml of Vildagliptin):

Further pipette 0.1ml of Vildagliptinfrom stock solutions in to a 10ml volumetric flask and dilute up to the mark with diluent.

Preparation of Level – IV (12µg/ml of Vildagliptin):

Further pipette 0.12ml of Vildagliptinfrom stock solutions in to a 10ml volumetric flask and dilute up to the mark with diluent.

Preparation of Level – V (14µg/ml of Vildagliptin):

Further pipette 0.14ml of Vildagliptin from stock solutions in to a 10ml volumetric flask and dilute up to the mark with diluent.

Procedure:

Inject each level into the chromatographic system and measure the peak area. Plot a graph of peak area versus concentration (on X-axis concentration and on Y-axis Peak area) and calculate the correlation coefficient.

Acceptance Criteria: Correlation coefficient[12] should be not less than 0.999.

Limit of Detection:

The detection limit[15] is determined by the analysis of samples with known concentration of analyte and by establishing that minimum level at which the analyte can reliably detected.

Limit of Quantitation

The quantification limit[16] is generally determined by the analysis of sample with known concentrations of analyte and by establishing the minimum level at which the analyte can be quantified with acceptable accuracy and precision.

Robustness:

The analysis was performed in different conditions to find the variability of test results. The following conditions are checked for variation of results. .

Effect of Variation of flow Rate:

The sample was analyzed at 0.9 ml/min and 1.1 ml/min instead of 1ml/min, remaining conditions are same. 20µl of the above sample was injected and chromatograms were recorded.

Effect of Variation of mobile phase organic composition:

The sample was analyzed by variation of mobile phase i.e. Acetonitrile: Phosphate Buffer was taken in the ratio

and 70:30, 75:25 instead of 65:35, remaining conditions are same. 20µl of the above sample was injected and chromatograms were recorded.

Forced Degradation Studies:

The specificity of the method can be demonstrated by applying stress conditions[17]using acid, alkaline, peroxide, thermal, UV, water degradations. The sample was exposed to these conditions the main peak of the drug was studied for peak purity that indicating the method effectively separated the degradation products from the pure active ingredient.

Acid Degradation Studies: To 1 ml of Vildagliptin stock, 1 ml of 2N HCl was added and refluxed for 30 min at 60 ºC. The resultant solution was neutralized with 1 ml 2N NaOH and makeup to final volume to obtain (10µg/ml) solution. Cool the solution to room temperature and filtered with 0.45µm membrane filter. A sample of 20µl was injected into the HPLC system, and the chromatograms were recorded to assess the stability of the sample.

Alkali Degradation Studies: To 1 ml of stock solution of Vildagliptin 1 ml of 2N sodium hydroxide was added and refluxed for 30 min at 60 ºC. The resultant solution was neutralized with 1 ml 2N HCl and makeup to final volume to obtain (10µg/ml) solution. Cool the solution to room temperature and filtered with 0.45µm membrane filter. The sample of 20µl was injected into the system, and the chromatograms were recorded to an assessment of sample stability.

Oxidation Degradation Studies: To 1 ml of stock solution of Vildagliptin 1 ml of 20% hydrogen peroxide (H_2O_2) was added separately. The solution was kept for 30 min at 60ºC.For HPLC study, the resultant solution was diluted to obtain (10µg/ml) solution. Cool the solution to room temperature and filtered with 0.45µm membrane filter. A sample of 20µl solution was injected into the system, and the chromatograms were recorded to assess the stability of the sample.

Dry Heat Degradation Studies: The 1 ml of standard drug solution was placed in the oven at 60ºC for 6h to study dry heat degradation. For HPLC study, the resultant solution was makeup to final volume to obtain (10µg/ml) solution. Cool the solution to room temperature and filtered through a 0.45µm membrane filter. A sample of 20µl solution was injected into the system, and the chromatograms were recorded for the assessment of sample stability.

Photo Degradation Studies: The photo stability of the drug was studied by exposing the stock solution to UV light for 1day or 200Watt-hours/m2 in photo stability chamber. For HPLC study, the resultant solution was diluted to obtain (10µg/ml) solution and filtered with 0.45µm membrane filter. A sample of 20µl solution was injected into the system, and the chromatograms were recorded for the assessment of sample stability.

Water Degradation Studies: To 1 ml of stock solution of Vildagliptin, 1 ml of distilled water was added. The solution was kept aside for 30 min at 60 ºC. For HPLC study, the resultant solution was diluted to obtain (10µg/ml) cool the solution to room temperature and filtered with 0.45µm membrane filter. A sample of 20µl was injected into the HPLC system, and the chromatograms were recorded for the assessment of sample stability.

III. RESULTS AND DISCUSSION

Method Development

Optimized Chromatographic Conditions:

Mobile phase : Acetonitrile: Phosphate buffer (0.01M, pH-3.2)(30:70v/v)
Column : Symmetry C_{18} ODS (4.6mm×250mm) 5µm particle size
Flow rate : 1.0 ml/min
Wavelength : 246 nm
Column temp : Ambient
Injection Volume : 20 µl
Run time : 10 minutes



Fig.4. Optimized Chromatographic Condition

Observation: In this trial it shows proper separation of peak and more plate count in the chromatogram and the tailing factor is within the limit. So it is an optimized chromatogram[18].

Preparation of 0.01M Potassium dihydrogen orthophosphate Buffer Solution:
About 1.36086grams of Potassium dihydrogen orthophosphate was weighed and transferred into a 1000ml beaker, dissolved and diluted to 1000ml with HPLC Grade water. The pH was adjusted to 3.20 with diluted orthophosphoric acid.

Preparationof Standard Solution:
10 mg of Vildagliptin working standard was accurately weighed and transferred into a 10 ml clean dry volumetric flask. Add about 7 ml of diluents and sonicate to dissolve it completely and volume was made up to the mark with the same solvent which gave stock solution of 1000 ppm.
Further pipette 1 ml of the above stock solution into a 10 ml volumetric flask was diluted up to the mark with diluents (100 ppm solution).
Further 1 ml of prepared 100 ppm solution was pipetted into a 10 ml volumetric flask and was diluted up to the mark with diluents which gave 10 ppm Vildagliptin working standard solution. The solution was mixed well and filtered through 0.45µm filter.

Preparation of SampleSolution:
Twenty tablets were taken and the average weight was calculated as per the method prescribed in I.P. The weighed tablets were finally powdered and triturated well. A quantity of powder of Vildagliptin equivalent to 10mg were transferred to clean and dry 10 ml volumetric flask and 7 ml of HPLC grade methanol was added and the resulting solution was sonicated for 15 minutes. Make up the volume up to 10 ml with same solvent. Then 1 ml of the above solution was diluted to 10 ml with HPLC grade methanol. One ml (0.1 ml) of the prepared stock solution diluted to 10 ml and was filtered through membrane filter (0.45µm) and finally sonicated to degas[19].

Method Validation
System Suitability:

Table-3: Observation of System Suitability Parameters

S.No.	Parameter	Vildagliptin
1.	Retention Time (min)	5.453
2.	Theoretical Plates	6967
3.	Tailing factor	1.12
4.	Peak Area (AUC)	647856

The system suitability parameters were found to be within the specified limits for the proposed method.

Specificity

The ICH documents define specificity as the ability to assess unequivocally the analyte in the presence of components that may be expected to be present, such as impurities, degradation products, and matrix components. Analytical method was tested for specificity to measure accurately quantitates Vildagliptin in drug product.

$$\%ASSAY = \frac{\text{Sample area}}{\text{Standard area}} \times \frac{\text{Weight of standard}}{\text{Dilution of standard}} \times \frac{\text{Dilution of sample}}{\text{Weight of sample}} \times \frac{\text{Purity}}{100} \times \frac{\text{Weight of tablet}}{\text{Label claim}} \times 100$$

The % purity of Vildagliptinin present in the marketed pharmaceutical dosage form was found to be 99.85%.

Linearity

Table-4: Chromatographic Data for Linearity Study of Vildagliptin

Concentration µg/ml	Average Peak Area
6	468784
8	615798
10	768759
12	925748
14	1078765



Fig.5. Calibration Curve of Vildagliptin

Linearity Plot: The plot of Concentration (x) versus the Average Peak Area (y) data of Vildagliptin is a straight line.

Y = mx + c
Slope (m) = 76943
Intercept (c) = 1787
Correlation Coefficient (r) = 0.99

Validation Criteria: The response linearity[20] is verified if the Correlation Coefficient is 0.99 or greater.

Conclusion: Correlation Coefficient (r) is 0.99, and the intercept is 76943. These values meet the validation criteria.

Precision:

The precision[21] of an analytical procedure expresses the closeness of agreement (degree of scatter) between a series of measurements obtained from multiple sampling of the same homogeneous sample under the prescribed conditions.

Repeatability:

Obtained Six (6) replicates of 100% accuracy solution as per experimental conditions. Recorded the peak areas and calculated % RSD.

Table-5: Results of Repeatability for Vildagliptin:

S. No.	Peak Name	Retention time	Area(µV*sec)	Height (µV)	USP Plate Count	USP Tailing
1	Vildagliptin	5.419	645784	83685	6825	1.05
2	Vildagliptin	5.405	642589	84932	6849	1.09
3	Vildagliptin	5.478	643658	85847	6845	1.08
4	Vildagliptin	5.466	648759	86295	6839	1.09
5	Vildagliptin	5.493	649657	86587	6895	1.07
6	Vildagliptin	5.466	647854	87853	6874	1.10
Mean			**646383.5**			
Std. Dev			**2853.319**			
%RSD			**0.441428**			

Intermediate Precision/Ruggedness:

Analyst 1:

Table-6: Results of Intermediate precision for Vildagliptin

S.No.	Peak Name	RT	Area (µV*sec)	Height (µV)	USP PlateCount	USP Tailing
1	Vildagliptin	5.484	636854	84863	6758	1.09
2	Vildagliptin	5.493	637489	84759	6726	1.08
3	Vildagliptin	5.406	635762	84685	6749	1.09
4	Vildagliptin	5.419	636984	84697	6698	1.07
5	Vildagliptin	5.446	634856	84258	6728	1.08
6	Vildagliptin	5.452	639689	84753	6699	1.08
Mean			**636939**			
Std.Dev.			**1649.149**			
%RSD			**0.258918**			

Analyst2:

Table-7: Results of Intermediate precision Analyst 2 for Vildagliptin

S.No.	Peak Name	RT	Area (µV*sec)	Height (µV)	USP Plate Count	USP Tailing

1	Vildagliptin	5.491	628985	85698	6985	1.09
2	Vildagliptin	5.482	624879	85479	6899	1.07
3	Vildagliptin	5.416	625846	85748	6928	1.06
4	Vildagliptin	5.482	623568	85647	6874	1.09
5	Vildagliptin	5.495	628985	85246	6984	1.07
6	Vildagliptin	5.427	628473	85924	6872	1.08
Mean			**626789.3**			
Std.Dev.			**2340.636**			
%RSD			**0.373433**			

Accuracy:

Accuracy[22] at different concentrations (50%, 100%, and 150%) was prepared and the % recovery was calculated.

Table-8: The Accuracy Results for Vildagliptin

%Concentration (at specification Level)	Area	Amount Added (ppm)	Amount Found (ppm)	% Recovery	Mean Recovery
50%	386559	5	5.00	100.000%	100.130%
100%	768536	10	9.965	99.650%	
150%	1164522	15	15.111	100.740%	

Limit of Detection for Vildagliptin

The detection limit of an individual analytical procedure is the lowest amount of analyte in a samplewhich can be detected but not necessarily quantitated as an exact value.

$$\mathbf{LOD = 3.3 \times \sigma / s}$$

Where,

σ = Standard deviation of the response

S = Slope of the calibration curve

Result:

= 0.487µg/ml

Quantitation Limit

The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined.

$$LOQ=10\times\sigma/S$$

Where,

σ = Standard deviation of the response

S = Slope of the calibration curve

Result:

= 1.477µg/ml

Robustness

The robustness[23] was performed for the flow rate variations from 0.9 ml/min to 1.1ml/min and mobile phase ratio variation from more organic phase to less organic phase ratio for Vildagliptin. The method is robust only in less flow condition. The standard of Vildagliptinwas injected by changing the conditions of chromatography. There was no significant change in the parameters like resolution, tailing factor, asymmetric factor, and plate count.

Table-9: Results for Robustness of Vildagliptin

Parameter used for Sample Analysis	Peak Area	Retention Time	Theoretical Plates	Tailing Factor
Actual Flow rate of 1.0 mL/min	648759	5.484	6845	1.08
Less Flow rate of 0.9 mL/min	635248	5.599	6786	1.09
More Flow rate of 1.1 mL/min	659865	4.576	6528	1.05
Less organic phase	625986	7.415	6689	1.03
More organic phase	615869	3.827	6354	1.01

Forced Degradation Studies:

The specificity of the method can be demonstrated by applying stress conditions[24-25]using acid, alkaline, peroxide, thermal, UV, water degradations. The sample was exposed to these conditions the main peak of the drug was studied for peak purity that indicating the method effectively separated the degradation products from the pure active ingredient.

Table-10: Results of Forced Degradation Studies for Vildagliptin

S.No.	Stress Condition	Peak Area	% of Degraded Amount	% of Active Amount	Total % of Amount
1	Standard	648759	0	100%	100%
2	Acidic	539378.232	16.86	83.14	100%
3	Basic	603540.497	6.97	93.03	100%
4	Oxidative	545217.063	15.96	84.04	100%
5	Thermal	616450.801	4.98	95.02	100%
6	Photolytic	533344.773	17.79	82.21	100%
7	Water	625079.296	3.65	96.35	100%

IV. SUMMARY AND CONCLUSION

The analytical method was developed by studying different parameters.First of all, maximum absorbance was

found to be at 246nm and the peak purity was excellent. Injection volume was selected to be 20µl which gave a good peak area. The column used for study was Symmetry C18 ODS (4.6mm×250mm) 5µm particle sizebecause it was giving good peak. Ambient temperature was found to be suitable for the nature of drug solution. The flow rate was fixed at 1.0ml/min because of good peak area and satisfactory retention time. Mobile phase is Acetonitrile: Phosphate buffer (0.01M, pH-3.2) (30:70% v/v) was fixed due to good symmetrical peak. So this mobile phase was used for the proposed study. Methanol was selected because of maximum extraction sonication time was fixed to be 10min at which all the drug particles were completely soluble and showed good recovery. Run time was selected to be 10min because analyze gave peak around 5.453min and also to reduce the total run time.The percent recovery was found to be 98.0-102 was linear and precise over the same range. Both system and method precision was found to be accurate and well within range. The analytical method was found linearity over the range of 6-14ppm of theVildagliptin Magnesium Trihydrate target concentration. The analytical passed both robustness and ruggedness tests. On both cases, relative standard deviation was well satisfactory.

REFENCES

1. https://go.drugbank.com/drugs/DB04876
2. https://pubchem.ncbi.nlm.nih.gov/compound/Galvus
3. https://en.wikipedia.org/wiki/Vildagliptin
4. Instrumental Analysis, Skoog, Fifth edition, Page no. 312-316.
5. Instrumental methods of chemical analysis, Gurdeep R. Chatwal. Page no2.116-2.122.
6. Elementary organic analysis, Principles and chemical applications, Y R Sharma, page no12-14.
7. A textbook of pharmaceutical analysis, Kasturi A V, Vol 3 10th ed., 169-81.
8. Willard-Hobart H, Merritt Jr Lynne L, Dean John A (1974) Instrumental Methods of Analysis. (5thedn), Von Nostrand, University of Michigan.
9. Chatwal GR, Anand S (2002) Instrumental Methods of Chemical Analysis. (5thedn), Himalaya Publishing House, New Delhi.
10. Davidson AG (2002) Ultraviolet-visible absorption Spectrophotometry. In Beckett AH, Stenlake JB, (4thedn), Practical Pharmaceutical chemistry. CBS Publishers and distributors, New Delhi, 275-278.
11. Robert AN, Pharmaceutical process validation, publisher Marcel Dekker, Inc, 2003; 507-522.
12. Text on Validation of Analytical Procedures Q2A in; I.C.H. Harmonized Tripartite Guidelines, Oct. 1994.
13. Text on Validation of Analytical Procedures Q2B in; I.C.H. Harmonized Tripartite Guidelines, Nov. 1996.
14. Indian Pharmacopoeia 2014, published by the Indian Pharmacopeia commission Ghaziabad: 2191-2194.
15. USP NF, The Official Compendia of Standards, Asian edition. 2008, 2662-2663.
16. British Pharmacopeia 2004 amended by supplements, 4.1-4.8 inclusive: 2577.
17. Wegscheider, Validation of Analytical Methods, in: Accreditation and Quality Assurance in Analytical Chemistry, H. Guenzler, Springer (Ed.) Verlag and Berlin 1996.
18. Validation of Analytical Procedures: Text and Methodology, ICH Harmonized Tripartite Guideline. Q2(R1), International Conference on Harmonization, Geneva,2005,1-13.
19. L.A. Woodward, Introduction to the Theory of Molecular Vibration and Vibrational Spectroscopy, Oxford University Press, London, 1972.
20. W.A. Guillory, Introduction to Molecular Structure and Spectroscopy, Allyn and Baccon Inc., Boston, 1977.
21. G. Herzberg, Infrared and Raman Spectra of Polyatomic Molecules, Van Nostrand, New York, 1964.
22. N.B. Colthup, L.H. Daly, S.E. Wiberely, Introduction to Infrared and Raman Spectroscopy, Academic press, New York, 1964.
23. G.F. Dyke, A.J. Floyd, M. Sainsbyrg, R.S. Theobald, Organic Spectroscopy: An Introduction, Longman Inc., New York, 1981.
24. D.N. Satyanarayana, Vibrational Spectroscopy Theory and Application, New Age International publishers, New Delhi, 2004.
25. R.E. Dpdd. Chemical Spectroscopy, Elsevier Publishing Company, New York, 1962. [10] S.D. Ross, Inorganic Infrared and Raman spectra, Mc Graw-Hill, London, 1972.
26. Aparajita Malakar*, Bishwajit Bokshi, Dilruba Nasrin, Development and Validation of RP-HPLC Method for Estimation of Vildagliptin from Tablet Dosage Form, International Journal of Pharmaceutical and Life Sciences Volume 1, Issue 1, Serial 2: August 2012, Pages: 1-8.
27. Jagdale Ramkrishna Raosaheb*1 Dabhade M. P.2 Kokate Shekhar Vikram1 , Shinde Vikas Sanjay1 and Shaikh Wasim Chand1, RP-HPLC Method Development and Validation of Vildagliptin in Bulk and Dosage Form, World Journal of Pharmacy and Pharmaceutical Sciences, Volume 6, Issue 9, 1161-1176.
28. Pragati Ranjan Satpathy*1, V. Mohan Goud1, Bhoga Bhagya2, JVC. Sharma1 & N.Shyamala1, Development and Validation of a RP-HPLC Method for the Assay of Vildagliptin, World Journal of Pharmacy and Pharmaceutical Sciences, Volume 3, Issue 2, 2303-2310.
29. Meetali M. Chaphekar* , Purnima D. Hamrapurkar, Development and Validation of RP-HPLC Assay Method for Vildagliptin Using Qbd Approach and Its Application to Forced Degradation Studies, International Journal of Pharmaceutical Sciences and Drug Research 2016; 8(3): 157-165.